HER-2 negative breast cancer is an aggressive type of breast cancer that lacks human epidermal growth factor receptor 2 (HER2) protein over-expression or HER2 gene amplification. The conventional treatment of HER-2 negative breast cancer involves a combination of surgery, chemotherapy and radiation therapy depending on the stage and characteristics of cancer. New targeted therapies are being developed to improve the treatment outcomes for these patients.

The global HER-2 Negative Breast Cancer Market is estimated to be valued at US$ 15982.51 Bn in 2023 and is expected to exhibit a CAGR of 10.% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.

Market Dynamics:

Increasing prevalence of HER-2 negative breast cancer is one of the key drivers boosting the growth of the market. According to the American Cancer Society, over 80% of breast cancer cases are diagnosed as HER2-negative breast cancer. Moreover, increasing research activities focused on development of novel targeted therapies for advanced Global HER-2 Negative Breast Cancer Market Size such as Puma Biotechnology Inc’s neratinib is gaining greater recognition over traditional chemotherapy. Neratinib can significantly extend life expectancy and progression-free survival rates in patients with advanced HER-2 negative breast cancer. Hence, availability of targeted therapies with better clinical outcomes compared to chemotherapy is fueling the HER-2 negative breast cancer market growth during the forecast period.

SWOT Analysis

Strength: The HER-2 negative breast cancer market has a large target patient population as HER-2 negative breast cancer represents approximately 70% of all breast cancer cases globally. Extensive R&D activities by market players to develop effective targeted therapies is expected to enhance treatment outcomes. Growing clinical trial activities for evaluating pipeline candidates is also driving the market growth.

Weakness: High costs associated with drug development and regulatory approvals are major challenges faced by market players. Limited breakthrough treatment options and high relapse rates also restrict the market growth to some extent.

Opportunity: Emerging economies such as China, India, Brazil, Mexico, and South Africa offer lucrative market opportunities attributed to increasing healthcare investments. Rising awareness levels regarding early cancer detection and treatment also creates growth prospects.

Threats: Risk of drug failure and stringent regulations for drug approvals are major threats faced by market players. Patent expiries of blockbuster drugs also impact the market revenues negatively.

Key Takeaways

The global HER-2 negative breast cancer market is expected to witness high growth over the forecast period. The market size for 2024 is projected to be US$ 15982.51 Bn, growing at a CAGR of 10% between 2024-2031.

Regional analysis: North America currently dominates the global market and is expected to maintain its leading position during the forecast period. This can be attributed to rising incidence rates, availability of advanced diagnostic and treatment options, and growing awareness levels regarding early detection.
Asia Pacific is forecasted to exhibit the fastest growth rate over the next few years owing to increasing healthcare spending, large untapped opportunities, and growing focus of global market players.

Key players operating in the HER-2 negative breast cancer market are Robert Bosch GmbH (Germany), HELLA KGaA (Germany), Continental AG (Germany), Denso Corporation (Japan), Delphi Automotive PLC (U.K.), Autoliv Inc. (Sweden), and Valeo S.A. (France) are the system manufacturers and companies such as Infineon Technologies AG (Germany).

Get More Insights On This Topic: https://www.trendingwebwire.com/her-2-negative-breast-cancer-market-size-share-analysis-2023-2030/